{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:35:00Z","timestamp":1787726100808,"version":"build-2784847793"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Although \u03b2-amyloid (A\u03b2) may be the primary driver of Alzheimer\u2019s disease (AD) pathology, accumulation of pathological tau correlates with dementia in AD patients. Thus, the prevention\/inhibition of AD may require vaccine\/s targeting A\u03b2 and tau simultaneously or sequentially. Since high antibody titers are required for AD vaccine efficacy, we have decided to generate vaccines, targeting A\u03b2 (AV-1959R), Tau (AV-1980R) or A\u03b2\/tau (AV-1953R) B cell epitopes, based on immunogenic MultiTEP platform and evaluate the immunogenicity of these vaccines formulated with Advax\n                    <jats:sup>CpG<\/jats:sup>\n                    , delta inulin, Alhydrogel\n                    <jats:sup>\u00ae<\/jats:sup>\n                    , Montanide-\n                    <jats:italic>ISA51<\/jats:italic>\n                    , Montanide-\n                    <jats:italic>ISA720<\/jats:italic>\n                    , MPLA-SM pharmaceutical grade adjuvants. Formulation of AV-1959R in Advax\n                    <jats:sup>CpG<\/jats:sup>\n                    induced the highest cellular and humoral immune responses in mice. The dual-epitope vaccine, AV-1953R, or the combination of AV-1959R and AV-1980R vaccines formulated with Advax\n                    <jats:sup>CpG<\/jats:sup>\n                    induced robust antibody responses against various forms of both, A\u03b2 and tau pathological molecules. While anti-A\u03b2 antibody titers after AV-1953R immunization were similar to that in mice vaccinated with AV-1959R or AV-1959R\/AV-1980R combination, anti-tau titers were significantly lower after AV-1953R injection when compared to the AV-1980R or AV-1959R\/AV-1980R.\n                    <jats:italic>In silico<\/jats:italic>\n                    3D-modeling provided insight into the differences in immunogenicity of these vaccine constructs. In sum, AV-1959R and AV-1980R formulated with Advax\n                    <jats:sup>CpG<\/jats:sup>\n                    adjuvant were identified as promising immunogenic vaccines for ongoing pre-clinical assessment and future human clinical trials.\n                  <\/jats:p>","DOI":"10.1038\/srep28912","type":"journal-article","created":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T06:26:27Z","timestamp":1467354387000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Alzheimer\u2019s disease AdvaxCpG- adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and A\u03b2 pathological molecules"],"prefix":"10.1038","volume":"6","author":[{"given":"Hayk","family":"Davtyan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Zagorski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harinda","family":"Rajapaksha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armine","family":"Hovakimyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arpine","family":"Davtyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Petrushina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin","family":"Kazarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Cribbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolai","family":"Petrovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Agadjanyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anahit","family":"Ghochikyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,1]]},"reference":[{"key":"BFsrep28912_CR1","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1097\/00005072-199409000-00003","volume":"53","author":"DJ Selkoe","year":"1994","unstructured":"Selkoe, D. J. Alzheimer\u2019s disease: a central role for amyloid. J Neuropath and Exp Neurology 53, 438\u2013447 (1994).","journal-title":"J Neuropath and Exp Neurology"},{"key":"BFsrep28912_CR2","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.coi.2004.07.012","volume":"16","author":"D Schenk","year":"2004","unstructured":"Schenk, D., Hagen, M. & Seubert, P. Current progress in beta-amyloid immunotherapy. Curr Opin Immunol 16, 599\u2013606 (2004).","journal-title":"Curr Opin Immunol"},{"key":"BFsrep28912_CR3","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/nri1843","volume":"6","author":"HL Weiner","year":"2006","unstructured":"Weiner, H. L. & Frenkel, D. Immunology and immunotherapy of Alzheimer\u2019s disease. Nat Rev Immunol 6, 404\u2013416 (2006).","journal-title":"Nat Rev Immunol"},{"key":"BFsrep28912_CR4","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3389\/fneur.2013.00093","volume":"4","author":"JE Gerson","year":"2013","unstructured":"Gerson, J. E. & Kayed, R. Formation and propagation of tau oligomeric seeds. Front Neurol 4, 93 (2013).","journal-title":"Front Neurol"},{"key":"BFsrep28912_CR5","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/bpa.12044","volume":"23","author":"F Clavaguera","year":"2013","unstructured":"Clavaguera, F. et al. \u201cPrion-like\u201d templated misfolding in tauopathies. Brain Pathol 23, 342\u2013349 (2013).","journal-title":"Brain Pathol"},{"key":"BFsrep28912_CR6","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.neuron.2013.07.046","volume":"80","author":"K Yanamandra","year":"2013","unstructured":"Yanamandra, K. et al. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 80, 402\u2013414 (2013).","journal-title":"Neuron"},{"key":"BFsrep28912_CR7","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/nrn2786","volume":"11","author":"B Frost","year":"2010","unstructured":"Frost, B. & Diamond, M. I. Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci 11, 155\u2013159 (2010).","journal-title":"Nat Rev Neurosci"},{"key":"BFsrep28912_CR8","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/nrn2194","volume":"8","author":"C Ballatore","year":"2007","unstructured":"Ballatore, C., Lee, V. M. & Trojanowski, J. Q. Tau-mediated neurodegeneration in Alzheimer\u2019s disease and related disorders. Nat Rev Neurosci 8, 663\u2013672 (2007).","journal-title":"Nat Rev Neurosci"},{"key":"BFsrep28912_CR9","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s00401-010-0719-5","volume":"120","author":"D Boche","year":"2010","unstructured":"Boche, D., Denham, N., Holmes, C. & Nicoll, J. A. Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer\u2019s disease pathogenesis. Acta Neuropathol 120, 369\u2013384 (2010).","journal-title":"Acta Neuropathol"},{"key":"BFsrep28912_CR10","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.jalz.2013.12.003","volume":"10","author":"H Davtyan","year":"2014","unstructured":"Davtyan, H. et al. The MultiTEP platform-based Alzheimer\u2019s disease epitope vaccine activates a broad repertoire of T helper cells in nonhuman primates. Alzheimers Dement 10, 271\u2013283 (2014).","journal-title":"Alzheimers Dement"},{"key":"BFsrep28912_CR11","doi-asserted-by":"publisher","first-page":"190","DOI":"10.2174\/1566523214666140522121427","volume":"14","author":"H Davtyan","year":"2014","unstructured":"Davtyan, H. et al. BTX AgilePulse(TM) system is an effective electroporation device for intramuscular and intradermal delivery of DNA vaccine. Curr Gene Ther 14, 190\u2013199 (2014).","journal-title":"Curr Gene Ther"},{"key":"BFsrep28912_CR12","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.4161\/hv.23875","volume":"9","author":"A Ghochikyan","year":"2013","unstructured":"Ghochikyan, A. et al. Refinement of a DNA based Alzheimer\u2019s disease epitope vaccine in rabbits. Hum Vaccin Immunother 9, 1002\u20131010 (2013).","journal-title":"Hum Vaccin Immunother"},{"key":"BFsrep28912_CR13","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.jalz.2013.04.505","volume":"10","author":"CF Evans","year":"2014","unstructured":"Evans, C. F. et al. Epitope-based DNA vaccine for Alzheimer\u2019s disease: Translational study in macaques. Alzheimers Dement 10, 284\u2013295 (2014).","journal-title":"Alzheimers Dement"},{"key":"BFsrep28912_CR14","doi-asserted-by":"publisher","first-page":"12776","DOI":"10.1523\/JNEUROSCI.3463-09.2009","volume":"29","author":"GA Morfini","year":"2009","unstructured":"Morfini, G. A. et al. Axonal transport defects in neurodegenerative diseases. J Neurosci 29, 12776\u201312786 (2009).","journal-title":"J Neurosci"},{"key":"BFsrep28912_CR15","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1042\/BST20120134","volume":"40","author":"SM Ward","year":"2012","unstructured":"Ward, S. M., Himmelstein, D. S., Lancia, J. K. & Binder, L. I. Tau oligomers and tau toxicity in neurodegenerative disease. Biochem Soc Trans 40, 667\u2013671 (2012).","journal-title":"Biochem Soc Trans"},{"key":"BFsrep28912_CR16","doi-asserted-by":"publisher","first-page":"e815","DOI":"10.1016\/j.neurobiolaging.2011.06.006","volume":"33","author":"NM Kanaan","year":"2012","unstructured":"Kanaan, N. M. et al. Phosphorylation in the amino terminus of tau prevents inhibition of anterograde axonal transport. Neurobiol Aging 33(826), e815\u2013830 (2012).","journal-title":"Neurobiol Aging"},{"key":"BFsrep28912_CR17","doi-asserted-by":"publisher","first-page":"9659","DOI":"10.1038\/srep09659","volume":"5","author":"M Derisbourg","year":"2015","unstructured":"Derisbourg, M. et al. Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms. Sci Rep 5, 9659 (2015).","journal-title":"Sci Rep"},{"key":"BFsrep28912_CR18","doi-asserted-by":"publisher","first-page":"5920","DOI":"10.1016\/j.vaccine.2015.09.030","volume":"33","author":"N Petrovsky","year":"2015","unstructured":"Petrovsky, N. & Cooper, P. D. Advax, a novel microcrystalline polysaccharide particle engineered from delta inulin, provides robust adjuvant potency together with tolerability and safety. Vaccine, 33, 5920\u20135926 (2015).","journal-title":"Vaccine"},{"key":"BFsrep28912_CR19","doi-asserted-by":"publisher","first-page":"5373","DOI":"10.1016\/j.vaccine.2012.06.021","volume":"30","author":"Y Honda-Okubo","year":"2012","unstructured":"Honda-Okubo, Y., Saade, F. & Petrovsky, N. Advax, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses. Vaccine 30, 5373\u20135381 (2012).","journal-title":"Vaccine"},{"key":"BFsrep28912_CR20","doi-asserted-by":"publisher","first-page":"6242","DOI":"10.1016\/j.vaccine.2011.06.078","volume":"29","author":"RC Layton","year":"2011","unstructured":"Layton, R. C. et al. Delta inulin polysaccharide adjuvant enhances the ability of split-virion H5N1 vaccine to protect against lethal challenge in ferrets. Vaccine 29, 6242\u20136251 (2011).","journal-title":"Vaccine"},{"key":"BFsrep28912_CR21","doi-asserted-by":"publisher","first-page":"10324","DOI":"10.1128\/JVI.00480-13","volume":"87","author":"N Petrovsky","year":"2013","unstructured":"Petrovsky, N. et al. An inactivated cell culture Japanese encephalitis vaccine (JE-ADVAX) formulated with delta inulin adjuvant provides robust heterologous protection against West Nile encephalitis via cross-protective memory B cells and neutralizing antibody. J Virol 87, 10324\u201310333 (2013).","journal-title":"J Virol"},{"key":"BFsrep28912_CR22","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1128\/JVI.02980-14","volume":"89","author":"Y Honda-Okubo","year":"2015","unstructured":"Honda-Okubo, Y. et al. Severe Acute Respiratory Syndrome-Associated Coronavirus Vaccines Formulated with Delta Inulin Adjuvants Provide Enhanced Protection while Ameliorating Lung Eosinophilic Immunopathology. J Virol 89, 2995\u20133007 (2015).","journal-title":"J Virol"},{"key":"BFsrep28912_CR23","doi-asserted-by":"publisher","first-page":"5407","DOI":"10.1016\/j.vaccine.2012.06.009","volume":"30","author":"DL Gordon","year":"2012","unstructured":"Gordon, D. L. et al. Randomized clinical trial of immunogenicity and safety of a recombinant H1N1\/2009 pandemic influenza vaccine containing Advax polysaccharide adjuvant. Vaccine 30, 5407\u20135416 (2012).","journal-title":"Vaccine"},{"key":"BFsrep28912_CR24","doi-asserted-by":"publisher","first-page":"e0132003","DOI":"10.1371\/journal.pone.0132003","volume":"10","author":"L Li","year":"2015","unstructured":"Li, L., Honda-Okubo, Y., Li, C., Sajkov, D. & Petrovsky, N. Delta Inulin Adjuvant Enhances Plasmablast Generation, Expression of Activation-Induced Cytidine Deaminase and B-Cell Affinity Maturation in Human Subjects Receiving Seasonal Influenza Vaccine. PLoS ONE 10, e0132003 (2015).","journal-title":"PLoS ONE"},{"key":"BFsrep28912_CR25","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.4161\/hv.27882","volume":"10","author":"H Davtyan","year":"2014","unstructured":"Davtyan, H. et al. Immunogenicity of DNA- and recombinant protein-based Alzheimer Disease Epitope Vaccines. Hum Vaccin Immunother 10, 1248\u201355 (2014).","journal-title":"Hum Vaccin Immunother"},{"key":"BFsrep28912_CR26","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1038\/nm790","volume":"8","author":"J McLaurin","year":"2002","unstructured":"McLaurin, J. et al. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4\u201310 and inhibit cytotoxicity and fibrillogenesis. Nat Med 8, 1263\u20131269 (2002).","journal-title":"Nat Med"},{"key":"BFsrep28912_CR27","unstructured":"Alzheimer\u2019s Disease International. World Alzheimer Report: The Global Impact of Dementia (2015)."},{"key":"BFsrep28912_CR28","first-page":"628070","volume":"2012","author":"K Lobello","year":"2012","unstructured":"Lobello, K., Ryan, J. M., Liu, E., Rippon, G. & Black, R. Targeting Beta amyloid: a clinical review of immunotherapeutic approaches in Alzheimer\u2019s disease. Int J Alzheimers Dis 2012, 628070 (2012).","journal-title":"Int J Alzheimers Dis"},{"key":"BFsrep28912_CR29","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1001\/jamaneurol.2013.5847","volume":"71","author":"GS Bloom","year":"2014","unstructured":"Bloom, G. S. Amyloid-beta and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol 71, 505\u2013508 (2014).","journal-title":"JAMA Neurol"},{"key":"BFsrep28912_CR30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/alzrt233","volume":"6","author":"TE Golde","year":"2014","unstructured":"Golde, T. E. Open questions for Alzheimer\u2019s disease immunotherapy. Alzheimers Res Ther 6, 3 (2014).","journal-title":"Alzheimers Res Ther"},{"key":"BFsrep28912_CR31","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/j.neuron.2014.12.064","volume":"85","author":"T Wisniewski","year":"2015","unstructured":"Wisniewski, T. & Goni, F. Immunotherapeutic approaches for Alzheimer\u2019s disease. Neuron 85, 1162\u20131176 (2015).","journal-title":"Neuron"},{"key":"BFsrep28912_CR32","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.molmed.2015.03.003","volume":"21","author":"JT Pedersen","year":"2015","unstructured":"Pedersen, J. T. & Sigurdsson, E. M. Tau immunotherapy for Alzheimer\u2019s disease. Trends Mol Med 21, 394\u2013402 (2015).","journal-title":"Trends Mol Med"},{"key":"BFsrep28912_CR33","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.jalz.2015.06.1884","volume":"11","author":"MG Agadjanyan","year":"2015","unstructured":"Agadjanyan, M. G., Petrovsky, N. & Ghochikyan, A. A fresh perspective from immunologists and vaccine researchers: Active vaccination strategies to prevent and reverse Alzheimer\u2019s disease. Alzheimers Dement 11, 1246\u20131259 (2015).","journal-title":"Alzheimers Dement"},{"key":"BFsrep28912_CR34","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","volume":"12","author":"CR Jack Jr.","year":"2013","unstructured":"Jack, C. R. Jr. et al. Tracking pathophysiological processes in Alzheimer\u2019s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 12, 207\u2013216 (2013).","journal-title":"Lancet Neurol"},{"key":"BFsrep28912_CR35","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1202753","volume":"367","author":"RJ Bateman","year":"2012","unstructured":"Bateman, R. J. et al. Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease. N Engl J Med 367, 795\u2013804 (2012).","journal-title":"N Engl J Med"},{"key":"BFsrep28912_CR36","first-page":"800","volume":"15","author":"Y Hang","year":"2015","unstructured":"Hang, Y. et al. Pharmacokinetic and Pharmacodynamic (PK\/PD) assessment and covariate analysis of BIIB037 in a randomized, double-blind, placebo-controlled, phase 1B study in patients with prodromal or mild alzheimer\u2019s disease. Neurodegener Dis 15 Suppl 1, 800 (2015).","journal-title":"Neurodegener Dis"},{"key":"BFsrep28912_CR37","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/ni.2588","volume":"14","author":"JJ Goronzy","year":"2013","unstructured":"Goronzy, J. J. & Weyand, C. M. Understanding immunosenescence to improve responses to vaccines. Nat Immunol 14, 428\u2013436 (2013).","journal-title":"Nat Immunol"},{"key":"BFsrep28912_CR38","doi-asserted-by":"publisher","first-page":"144","DOI":"10.2174\/156720509787602852","volume":"6","author":"B Vellas","year":"2009","unstructured":"Vellas, B. et al. Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr Alzheimer Res 6, 144\u2013151 (2009).","journal-title":"Curr Alzheimer Res"},{"key":"BFsrep28912_CR39","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1073\/pnas.0436286100","volume":"100","author":"F Bard","year":"2003","unstructured":"Bard, F. et al. Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer\u2019s disease-like neuropathology. Proc Natl Acad Sci USA 100, 2023\u20132028. (2003).","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFsrep28912_CR40","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1073\/pnas.1215165110","volume":"110","author":"JP Michaud","year":"2013","unstructured":"Michaud, J. P. et al. Toll-like receptor 4 stimulation with the detoxified ligand monophosphoryl lipid A improves Alzheimer\u2019s disease-related pathology. Proc Natl Acad Sci USA 110, 1941\u20131946 (2013).","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFsrep28912_CR41","doi-asserted-by":"publisher","first-page":"7027","DOI":"10.1523\/JNEUROSCI.5924-12.2013","volume":"33","author":"B Liu","year":"2013","unstructured":"Liu, B. et al. MER5101, a Novel Abeta1-15:DT Conjugate Vaccine, Generates a Robust Anti-Abeta Antibody Response and Attenuates Abeta Pathology and Cognitive Deficits in APPswe\/PS1DeltaE9 Transgenic Mice. J Neurosci 33, 7027\u20137037 (2013).","journal-title":"J Neurosci"},{"key":"BFsrep28912_CR42","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nrneurol.2009.219","volume":"6","author":"CA Lemere","year":"2010","unstructured":"Lemere, C. A. & Masliah, E. Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol 6, 108\u2013119 (2010).","journal-title":"Nat Rev Neurol"},{"key":"BFsrep28912_CR43","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/j.1471-4159.2011.07458.x","volume":"120","author":"J Delrieu","year":"2012","unstructured":"Delrieu, J., Ousset, P. J., Caillaud, C. & Vellas, B. \u2018Clinical trials in Alzheimer\u2019s disease\u2019: immunotherapy approaches. J Neurochem 120 Suppl 1, 186\u2013193 (2012).","journal-title":"J Neurochem"},{"key":"BFsrep28912_CR44","doi-asserted-by":"publisher","first-page":"12721","DOI":"10.1523\/JNEUROSCI.3201-07.2007","volume":"27","author":"I Petrushina","year":"2007","unstructured":"Petrushina, I. et al. Alzheimer\u2019s Disease Peptide Epitope Vaccine Reduces Insoluble But Not Soluble\/Oligomeric A\u03b2 Species in Amyloid Precursor Protein Transgenic Mice. J Neurosci 27, 12721\u201312731 (2007).","journal-title":"J Neurosci"},{"key":"BFsrep28912_CR45","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3233\/JAD-2008-15202","volume":"15","author":"EM Sigurdsson","year":"2008","unstructured":"Sigurdsson, E. M. Immunotherapy targeting pathological tau protein in Alzheimer\u2019s disease and related tauopathies. J Alzheimers Dis 15, 157\u2013168 (2008).","journal-title":"J Alzheimers Dis"},{"key":"BFsrep28912_CR46","doi-asserted-by":"publisher","first-page":"19855","DOI":"10.1074\/jbc.R114.549295","volume":"289","author":"BB Holmes","year":"2014","unstructured":"Holmes, B. B. & Diamond, M. I. Prion-like properties of Tau protein: the importance of extracellular Tau as a therapeutic target. J Biol Chem 289, 19855\u201319861 (2014).","journal-title":"J Biol Chem"},{"key":"BFsrep28912_CR47","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/acn3.176","volume":"2","author":"K Yanamandra","year":"2015","unstructured":"Yanamandra, K. et al. Anti-tau antibody reduces insoluble tau and decreases brain atrophy. Ann Clin Transl Neurol 2, 278\u2013288 (2015).","journal-title":"Ann Clin Transl Neurol"},{"key":"BFsrep28912_CR48","doi-asserted-by":"publisher","first-page":"4857","DOI":"10.1523\/JNEUROSCI.4989-14.2015","volume":"35","author":"DL Castillo-Carranza","year":"2015","unstructured":"Castillo-Carranza, D. L. et al. Tau immunotherapy modulates both pathological tau and upstream amyloid pathology in an Alzheimer\u2019s disease mouse model. J Neurosci 35, 4857\u20134868 (2015).","journal-title":"J Neurosci"},{"key":"BFsrep28912_CR49","doi-asserted-by":"publisher","first-page":"484","DOI":"10.2174\/138920101606150407112319","volume":"16","author":"C Yang","year":"2015","unstructured":"Yang, C. & Xiao, S. New developments of clinical trial in immunotherapy for Alzheimer\u2019s disease. Curr Pharm Biotechnol 16, 484\u2013491 (2015).","journal-title":"Curr Pharm Biotechnol"},{"key":"BFsrep28912_CR50","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1159\/000354491","volume":"13","author":"EM Sigurdsson","year":"2014","unstructured":"Sigurdsson, E. M. Tau immunotherapy and imaging. Neurodegener Dis 13, 103\u2013106 (2014).","journal-title":"Neurodegener Dis"},{"key":"BFsrep28912_CR51","doi-asserted-by":"publisher","first-page":"e0125614","DOI":"10.1371\/journal.pone.0125614","volume":"10","author":"S Sankaranarayanan","year":"2015","unstructured":"Sankaranarayanan, S. et al. Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models. PLoS One 10, e0125614 (2015).","journal-title":"PLoS One"},{"key":"BFsrep28912_CR52","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrm2101","volume":"8","author":"C Haass","year":"2007","unstructured":"Haass, C. & Selkoe, D. J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer\u2019s amyloid beta-peptide. Nat Rev Mol Cell Biol 8, 101\u2013112 (2007).","journal-title":"Nat Rev Mol Cell Biol"},{"key":"BFsrep28912_CR53","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/gt.2009.140","volume":"17","author":"H Davtyan","year":"2010","unstructured":"Davtyan, H. et al. DNA prime-protein boost increased the titer, avidity and persistence of anti-Abeta antibodies in wild-type mice. Gene Ther 17, 261\u2013271 (2010).","journal-title":"Gene Ther"},{"key":"BFsrep28912_CR54","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1371\/journal.pone.0002124","volume":"3","author":"N Movsesyan","year":"2008","unstructured":"Movsesyan, N. et al. Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine- a novel immunotherapeutic strategy. PLos ONE 3, e21\u201324 (2008).","journal-title":"PLos ONE"},{"key":"BFsrep28912_CR55","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1093\/intimm\/dxg049","volume":"15","author":"DH Cribbs","year":"2003","unstructured":"Cribbs, D. H. et al. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int. Immunol. 15, 505\u2013514 (2003).","journal-title":"Int. Immunol."},{"key":"BFsrep28912_CR56","doi-asserted-by":"publisher","first-page":"4923","DOI":"10.1523\/JNEUROSCI.4672-12.2013","volume":"33","author":"H Davtyan","year":"2013","unstructured":"Davtyan, H. et al. Immunogenicity, Efficacy, Safety and Mechanism of Action of Epitope Vaccine (Lu AF20513) for Alzheimer\u2019s Disease: Prelude to a Clinical Trial. J Neurosci 33, 4923\u20134934 (2013).","journal-title":"J Neurosci"},{"key":"BFsrep28912_CR57","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.4049\/jimmunol.174.3.1580","volume":"174","author":"MG Agadjanyan","year":"2005","unstructured":"Agadjanyan, M. G. et al. Prototype Alzheimer\u2019s disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J Immunol 174, 1580\u20131586 (2005).","journal-title":"J Immunol"},{"key":"BFsrep28912_CR58","first-page":"1916","volume":"38","author":"RF Rosen","year":"2010","unstructured":"Rosen, R. F., Tomidokoro, Y., Ghiso, J. A. & Walker, L. C. SDS-PAGE\/immunoblot detection of Abeta multimers in human cortical tissue homogenates using antigen-epitope retrieval. J Vis Exp 38, 1916 (2010).","journal-title":"J Vis Exp"},{"key":"BFsrep28912_CR59","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/bioinformatics\/16.4.404","volume":"16","author":"LJ McGuffin","year":"2000","unstructured":"McGuffin, L. J., Bryson, K. & Jones, D. T. The PSIPRED protein structure prediction server. Bioinformatics 16, 404\u2013405 (2000).","journal-title":"Bioinformatics"},{"key":"BFsrep28912_CR60","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0076-6879(03)74020-8","volume":"374","author":"A Fiser","year":"2003","unstructured":"Fiser, A. & Sali, A. Modeller: generation and refinement of homology-based protein structure models. Methods Enzymol 374, 461\u2013491 (2003).","journal-title":"Methods Enzymol"},{"key":"BFsrep28912_CR61","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1002\/jcc.20289","volume":"26","author":"JC Phillips","year":"2005","unstructured":"Phillips, J. C. et al. Scalable molecular dynamics with NAMD. J Comput Chem 26, 1781\u20131802 (2005).","journal-title":"J Comput Chem"},{"key":"BFsrep28912_CR62","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/jcc.20084","volume":"25","author":"EF Pettersen","year":"2004","unstructured":"Pettersen, E. F. et al. UCSF Chimera\u2013a visualization system for exploratory research and analysis. J Comput Chem 25, 1605\u20131612 (2004).","journal-title":"J Comput Chem"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep28912","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep28912.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep28912.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T12:55:08Z","timestamp":1672836908000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep28912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,1]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,9,1]]}},"alternative-id":["BFsrep28912"],"URL":"https:\/\/doi.org\/10.1038\/srep28912","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,1]]},"assertion":[{"value":"19 November 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.P. is a Director and H.R. an employee of Vaxine Pty Ltd, the developer of the Advax adjuvant technology. M.G.A. is co-founder of Neuroimmune that licensed MultiTEP vaccine platform technology from the Institute for Molecular Medicine. The remaining author(s) declare no financial and commercial conflict of interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28912"}}